GERN

Geron Corporation focuses on developing and commercializing therapies for blood cancers, specifically through the inhibition of the enzyme telomerase, which is linked to the uncontrolled growth of malignant cells. The company operates in the biotechnology sector, leveraging its expertise in research, clinical development, and regulatory processes to advance its therapeutic candidates. Geron's primary customers include healthcare providers and patients affected by hematologic malignancies, with its operations primarily based in the United States.